Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QN-023a in relapsed/refractory AML
NCT05601466Phase 1Terminated
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2022
- Primary completion
- Apr 2023
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QN-023a in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 28 days and Incidence of Dose Limiting Toxicities at 28 days. Started Mar 2022; status: terminated.
02
Drugs
QN-023a
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05601466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601466.